Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Angiogenesis and Ophthalmic Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PGF (Placental Growth Factor) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PGF (PlGF) Isoform Proteins (PlGF-1, PlGF-2) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed. |
View PGF Products |
| Receptor / Related Target | VEGFR1/FLT1 ECD-Fc Fusion Protein High purity (>95%), Sequence Verified for binding studies. |
View FLT1 Products |
| Gene Delivery | PGF Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View PGF Products |
| Benchmark Ab | Anti-PGF (Neutralizing) Recombinant positive control for bioassays. |
View PGF Products |
| Validator | PGF siRNA Set For knockdown verification and specificity controls. |
View PGF Products |
| Pathway Partner | VEGFA Competitive ligand for VEGFR1 binding assays. |
View VEGFA Products |
| Co-receptor | Neuropilin-1 (NRP1) PlGF-2 specific binding partner for isoform selectivity. |
View NRP1 Products |
Critical Assay Challenges & Technical Specifications
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (PlGF-1 vs PlGF-2) | Distinct Isoform Proteins: PlGF-1 (non-heparin binding) and PlGF-2 (heparin-binding) available separately, >95% purity, Sequence Verified. |
| VEGFR1/FLT1 Binding Competition | High-affinity VEGFR1/FLT1 ECD-Fc Protein: SPR/BLI compatible, Human/Mouse/Cyno orthologs available. |
| Cross-species Preclinical Translation | Human, Mouse, Cynomolgus, and Rabbit PGF ortholog proteins available with >95% purity, Endotoxin <1EU/ug for in vivo use. |
| Specificity & Controls | VEGFA Reference Protein & Clinical Benchmark Antibodies (Biosimilars) included for differential binding and off-target screening. Validated siRNA included for specificity checks. |
| Internalization Potential (ADC Development) | VEGFR1 Lentivirus Particles: generate stable overexpressing cell lines for internalization studies. |
| Subfamily Counter Screening (VEGF family) | Homolog panel proteins strictly verified by mass spec (VEGF-A, B, C, D). |
Live PGF/PlGF R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PGF/PlGF therapeutics is highly established in ophthalmology and expanding in oncology. With major players utilizing fusion proteins (e.g., VEGF-Trap) and multispecific antibodies, the focus is on dual-targeting VEGF-A and PlGF to overcome resistance to traditional anti-VEGF monotherapies. As first-generation therapies reach maturity, the next wave of R&D is targeting sustained delivery formulations, enhanced tissue penetration, isoform-selective inhibition (PlGF-1 vs PlGF-2), and novel bispecific combinations as well as PlGF-directed ADCs for refractory wet AMD and solid tumors. Preclinical development increasingly demands high-purity isoform proteins, cross-species orthologs, and VEGFR1-based internalization assays to support these advanced modalities.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Fusion Protein (Trap) | Regeneron, Bayer | Wet AMD, DME | Binding Affinity (Need high-purity ECDs) |
| Bispecific (VEGF/PlGF) | Regeneron, Bio-innovators | Wet AMD, DME, Oncology | Heterodimer competition assays (Need both antigens) |
| Monoclonal Antibody (Anti-PlGF) | Roche, Oxurion, ThromboGenics | Oncology, Diabetic Eye Disease, Solid Tumors | Isoform binding assays (Need PlGF-1 vs PlGF-2 proteins) |
| Antibody-Drug Conjugate (ADC) | Emerging Biotech | Solid Tumors | Internalization assay (Need VEGFR1+ stable cells) |